If further analysis of clinical ear tumor specimens shows non-mutational activation of EGFR, it is possible that EGFR inhibitors that were ineffective in our preclinical studies such as erlotinib or cetuximab might be effective clinically. The gene discussed is EGFR; the disease is neoplasm.